BNIP3 silencing by DNA methylation is a common event in many types of cancers [38, 39], and a clinical investigation suggested that the methylation frequency in the BNIP3 and BNIP3L promoters is associated with a poor prognosis for patients with HCC [40]. This evidence concerns the gene BNIP3L and cancer.